Advertisement
Advertisement
http://2015.eurothrombosis.eu

Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


Archive

Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Theme Issue
Immunology of atherosclerosis

DOI: http://dx.doi.org/10.1160/TH11-05-0358
Issue: 2011: 106/5 (Nov) pp. 753-992
Pages: 868-876

Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation

A consensus document of the Italian Federation of Thrombosis Centers (FCSA)

V. Pengo (1), L. Crippa (2), A. Falanga (3), G. Finazzi (4), F. Marongiu (5), G. Palareti (6), D. Poli (7), S. Testa (8), E. Tiraferri (9), A. Tosetto (10), A. Tripodi (11), C. Manotti (12)

(1) Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy; (2) Thrombosis Research Unit, IRCCS H S.Raffaele, Milan, Italy; (3) Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti, Bergamo, Italy; (4) Division of Hematology, Ospedali Riuniti, Bergamo, Italy; (5) Department of Medical Sciences, University Hospital, Cagliari, Italy; (6) Department of Angiology and Blood Coagulation "Marino Golinelli", University Hospital, Bologna, Italy; (7) Department of Heart and Vessels, Thrombosis Center, Careggi University Hospital, Firenze, Italy; (8) Thrombosis Centre, District Hospital, Cremona, Italy; (9) Haemostasis and Thrombosis Centre, City Hospital, Rimini, Italy; (10) Department of Hematology, San Bortolo Hospital, Vicenza, Italy; (11) Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Granda Maggiore Hospital Foundation and Università degli Studi di Milano, Milan, Italy; (12) Anticoagulation Service, Fidenza, Italy

Keywords

Clinical trials, prevention, heart, oral anticoagulants

Summary

Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.

You may also be interested in...

1.
Results from the national multicentre BNK Online bRiDging REgistRy (BORDER)

See also Editorial by Limantoro, Pisters

H. Omran (1), R. Bauersachs (2), S. Rübenacker (3), F. Goss (4), C. Hammerstingl (5)

Thromb Haemost 2012 108 1: 65-73

http://dx.doi.org/10.1160/TH11-12-0827

2.

D. A. Garcia (1), R. D. Lopes (2), E. M. Hylek (3)

Thromb Haemost 2010 104 6: 1099-1105

http://dx.doi.org/10.1160/TH10-07-0491

3.
A randomised primary prevention trial
V. Pengo (1), U. Cucchini (1), G. Denas (1), B. L. Davidson (2), F. Marzot (1), S. P. Jose (1), S. Iliceto (1)

Thromb Haemost 2010 103 2: 442-449

http://dx.doi.org/10.1160/TH09-05-0311